חוב כולל להון TriSalus Life Sciences Inc (TLSI)

This daily price chart for TriSalus Life Sciences (TLSI) illustrates the debt-to-equity ratio, which currently stands at 4.98. TriSalus Life Sciences is developing a targeted drug delivery system for neoplasms, leveraging the implementation of the PERIO method and the expansion of partnerships. Meanwhile, the business combines its own production of infusion equipment with the engagement of third-party CROs for testing. The financial position is complicated by a liquidity shortage and R&D expenditures.

This indicator determines the business's financial resilience to external shocks by comparing liabilities and equity. By analyzing the total debt-to-equity chart, an investor assesses the company's leverage level. The current value of 4.98 reflects the balance between borrowed leverage and internal resources. A low debt load minimizes bankruptcy risks. The catheter assembly outsourcing strategy of TriSalus Life Sciences (TLSI) reduces the need for capital expenditures, maintaining this stability.